UCSF and Mount Sinai researchers have used whole-organism screening in a Drosophila cancer model to identify and optimize a multitargeted kinase inhibitor with activity in a mouse model of medullary thyroid carcinoma. An undisclosed pharma is negotiating to license the IP.